Literature DB >> 20028266

Bilateral reversible corneal edema associated with amantadine use.

Salomon Esquenazi1.   

Abstract

PURPOSE: In this article, we report a case of bilateral severe reversible corneal edema caused by amantadine therapy. CASE: A 39-year-old women was referred to us for evaluation of bilateral corneal edema. Her past medical history was significant for multiple sclerosis, anorexia, and seizures. She developed painless progressive bilateral loss of vision for the past 6 months. She was evaluated by several ophthalmologists elsewhere who felt that the patient's visual loss was secondary to a nutritional deficiency as opposed to related to multiple sclerosis. She was started on vitamin B-12 medication without improvement in her symptoms. She was then evaluated by neuro-ophthalmology. The examination revealed severe bilateral corneal edema and was referred to our corneal service for further evaluation of her corneal condition. Our examination revealed best corrected visual acuity of 20/400 bilaterally. Corneal thickness was 940 microm in the right eye and 802 microm in the left. Color vision was intact. Conjunctivas were white bilaterally. Cornea evaluation revealed diffuse stromal edema and Descemet's folds and microcystic subepithelial edema with to guttae noted. Anterior chambers were deep and quiet. A specular microscopy revealed significant pleomorphism and polymegathism with an endothelial cell count of 1,504 cells in the right eye and 1,596 in the left eye.
RESULTS: Review of the patient's medical information revealed therapy with amantadine 2 months prior to the appearance of the patient's symptoms as a means to control the patient's tremors. The patient experienced rapid resolution of the corneal edema within the next 2 months after discontinuation of the agent with recovery of best corrected visual acuity of 20/40 in the right eye and 20/30 in the left.
CONCLUSIONS: In cases of unexplained corneal edema and in the absence of any identifiable ocular cause, a review of toxic effects of systemic medications should be performed. Early diagnosis may prevent irreversible endothelial damage. Amantadine can cause endothelial failure and needs to be considered as part of the differential diagnosis of corneal edema.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028266      PMCID: PMC3096536          DOI: 10.1089/jop.2009.0029

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  12 in total

Review 1.  Ocular complications of neurological therapy.

Authors:  S Hadjikoutis; J E Morgan; J M Wild; P E M Smith
Journal:  Eur J Neurol       Date:  2005-07       Impact factor: 6.089

2.  Topiramate-induced acute-onset myopia and central corneal thickening: Pentacam Scheimpflug imaging findings.

Authors:  Hurkan Kerimoglu; Mine Tokgoz; Banu Ozturk; Saban Gonul; Hamiyet Pekel
Journal:  Can J Ophthalmol       Date:  2009-04       Impact factor: 1.882

3.  Toxic corneal oedema associated with amantadine use.

Authors:  A Pond; M S Lee; D R Hardten; A R Harrison; J H Krachmer
Journal:  Br J Ophthalmol       Date:  2009-03       Impact factor: 4.638

4.  Reversible corneal edema associated with amantadine use: an unrecognized problem.

Authors:  Jordan S Dubow; Michael Rezak; Andrew A Berman
Journal:  Mov Disord       Date:  2008-10-30       Impact factor: 10.338

5.  Posterior collagenous layer of the cornea. Ultrastructural classification of abnormal collagenous tissue posterior to Descemet's membrane in 30 cases.

Authors:  G O Waring
Journal:  Arch Ophthalmol       Date:  1982-01

6.  Reversible amantadine-induced corneal edema in an adolescent.

Authors:  Bradley Hughes; Vahid Feiz; Steven B Flynn; Michael C Brodsky
Journal:  Cornea       Date:  2004-11       Impact factor: 2.651

7.  Fluoxetine inhibits K(+) transport pathways (K(+) efflux, Na(+)-K(+)-2Cl(-) cotransport, and Na(+) pump) underlying volume regulation in corneal endothelial cells.

Authors:  E Hara; P S Reinach; Q Wen; P Iserovich; J Fischbarg
Journal:  J Membr Biol       Date:  1999-09-01       Impact factor: 1.843

8.  [Keratitis and corneal edema associated with levodopa use--a case report].

Authors:  K Nakamagoe; N Ohkoshi; T Fujita; S Hoshino; S Shoji
Journal:  Rinsho Shinkeigaku       Date:  1996-07

9.  Amantadine-associated corneal edema potentially irreversible even after cessation of the medication.

Authors:  Bennie H Jeng; Anat Galor; Michael S Lee; David M Meisler; Joe G Hollyfield; Lynn Schoenfield; James T McMahon; Roger H S Langston
Journal:  Ophthalmology       Date:  2008-05-23       Impact factor: 12.079

10.  Corneal endothelial dysfunction associated with amantadine toxicity.

Authors:  Ki Cheol Chang; Mee Kum Kim; Won Ryang Wee; Jin Hak Lee
Journal:  Cornea       Date:  2008-12       Impact factor: 2.651

View more
  5 in total

1.  Management of recurrent acute bilateral corneal endotheliitis monitored by serial corneal pachymetry.

Authors:  B V Rao; Devika S Joshi; Sandeep Gupta; P S Moulick
Journal:  Med J Armed Forces India       Date:  2016-03-02

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  The effect of systemic amantadine sulfate on malondialdehyde and total thiol levels in rat corneas.

Authors:  Züleyha Yalniz-Akkaya; Vildan Fidanci; Aytul Kilinc; Ayse Burcu; Guner O Uney; Firdevs Ornek
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep

4.  Clinical and genetic investigation of amantadine-associated corneal edema.

Authors:  Michelle M Hessen; Sina Vahedi; Chloe T Khoo; Gelareh Vakili; Allen O Eghrari
Journal:  Clin Ophthalmol       Date:  2018-08-06

Review 5.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.